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Background/aim: FLT-3 ligand is a growth factor affecting the hematopoietic lineage. The aim of this study was to evaluate the variability
of peripheral FLT-3 ligand during the clinical course of acute myeloid leukemia (AML) patients.
Materials and methods: Twenty-four patients were enrolled in this study in order to assess alterations in the circulating levels of FLT-3
ligand during the clinical course of AML.
Results: We studied the association in the diagnostic period between the FLT-3 ligand and peripheral blood cells together with serum
electrolytes. FLT-3 ligand levels (pg/mL) during the aplastic period due to remission induction and consolidation were higher than the
levels at initial diagnosis. On the other hand, the diagnostic and remission induction values of leukocytes and FLT-3 ligand showed an
inverse association. These results indicate to us that higher white cell counts are associated with lower FLT-3 ligand levels. We also found
a reversed association between FLT-3 ligand and serum lactate dehydrogenase level. However, there was no association between FLT-3
ligand and other serum electrolyte levels. We also found higher FLT-3 ligand levels in male patients.
Conclusion: Our study demonstrates the inverse proliferative action of FLT-3 ligand on the early myeloid lineage. In addition, this study
showed us that FLT-3 receptor inhibition during chemotherapy-induced aplasia causes a compensative ligand overexpression.
Key words: Acute myeloid leukemia, FLT-3 ligand

1. Introduction
Acute myeloid leukemia (AML) is a process of increased
myeloid cells in the bone marrow with maturation arrest.
The progress of this situation leads to hematopoietic
insufficiency (granulocytopenia, thrombocytopenia, or
anemia), with or without leukocytosis (1). The progression
of the leukemic blast cells is regulated by exogenous and
endogenous human growth factors (2,3).
The FLT-3 ligand plays a role in complex cytokine
interactions in the process of proliferation and
differentiation of various hematologic periods while it is a
router in early cell interactions (4–6). The FLT-3 receptor
is a transmembrane protein that reaches its biologically
active form by proteolytic lysis. It was suggested that
with its proliferative activity, the FLT-3 ligand also has an
antitumor effect (7). The FLT-3 ligand is an earlier releaser
of the progenitor cells from the stem cell pool according
to GM-CSF and G-CSF actions, which occur later.
Additionally, a study on mouse models showed that the
FLT-3 ligand increases the blood amount of CD34 cells.
* Correspondence: memsahinsahin@hotmail.com

These features gave rise to the idea that recombinant FLT3 ligand could be used in bone marrow transplantation to
evoke cell mobilization. Similarly, some authors theorized
that the FLT-3 ligand could be used in many pathological
diseases such as Fanconi and aplastic anemia that
originated from stem cell defects (8).
FLT-3 ligand binding to the tyrosine kinase receptor
system and the juxtamembranous region with the
activation of the kinase domain mutation of most AML
and acute lymphoblastic leukemia (ALL) patients was
identified. Initial studies showed some benefit of FLT-3
inhibition in high-risk AML patients (9).
The aim of this study was to evaluate the variability
of peripheral FLT-3 ligand during the clinical course of
AML patients. In this context, the change of some critical
parameters in the clinical course of AML such as white
cell, platelet, and electrolyte levels and infection, age, and
sex were analyzed according to the differentiation of the
FLT-3 ligand. While FLT-3 receptor mutations developed
in patients with AML are known to be associated with
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poor prognosis in younger patients, the effect of outside
ligand stimulation is not fully understood.
Due to its critical role in the pathogenesis of AML cell
proliferation, understanding the critical role of the FLT-3
ligand serves the objective of the development of targeted
therapeutic approaches.
2. Materials and methods
This study was conducted with 24 AML patients who
were diagnosed in the Hacettepe University Hematology
Department between 2002 and 2003. Informed consent
from all patients and ethical permission (Hacettepe
University Ethical Committee) were obtained. The
inclusion criteria were:
1- A new diagnosis of AML or a myeloid transformation
of chronic myeloid leukemia.
2- Patient provision of informed consent.
Exclusion criteria were:
1- Patients with renal failure (creatinine value over 1.5
mg/dL).
2- Patients with abnormality in liver function tests
(alanine transaminase higher than 1.5 times the
normal value).
3- Patients who did not provide informed consent.
Plasma FLT-3 ligand analysis was performed with the
sandwich enzyme immunoassay technique (Quantikine,
R&D Systems; Minneapolis, MN, USA; Catalog Number:
308-DFK00). All blood samples were collected in the
morning hours to avoid possible diurnal variation,
although there is no standard literature about the diurnal
variation of the Flt-3 ligand. Remission-induction therapy
was administered to AML patients as cytarabine at 200 mg
mm–2 day–1 (7 days) + idarubicin at 13 mg mm–2 day–1 (3
days) and consolidation treatment was performed with
cytarabine at 3 g m–2 every 12 h (days 1, 3, and 5). Only
nine of the patients’ FLT-3 ligand evaluations during the
treatment periods could be completed. Blood samples were
collected during 5 periods: 1- first diagnosis, 2- aplastic
term (at the time of lowest platelet count) of idarubicin
+ cytarabine chemotherapy, 3- before consolidation
treatment (during normal cell count), 4- cytopenic
period of the consolidation treatment, and 5- after the
consolidation treatment.
Statistical analysis was performed with SPSS 10.
Because of the wide range of measurements and the low
number of patients, nonparametric tests were preferred in
our analysis. Friedman analysis was used to compare the
FLT-3 ligand values for the same group in different time
periods. Analysis of different groups was performed with
the Wilcoxon test. Spearman analysis was used to test FLT3 ligand variation and white cell, platelet, and hemoglobin
change. The Mann–Whitney U test was used to measure
the differences of sex and body temperature variation.
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3. Results
There were 24 newly diagnosed AML patients in our study.
Diagnostic FLT-3 ligand, white cell, and platelet levels were
measured for all patients. Serum lactate dehydrogenase
(LDH) and electrolyte levels were also measured at
diagnosis in the study group. Demographic characteristics
and the AML subtypes of patients are summarized in Table
1. Only nine of the patients’ FLT-3 ligand evaluations
during the treatment periods could be completed.
At the time of diagnosis, the median FLT-3 ligand
value was 139 pg/mL (minimum: 6.88 pg/mL; maximum:
1419 pg/mL; interquartile range (IQR): 41.94). The
median white cell value was 12 × 103/µL (minimum: 3 ×
103/µL; maximum: 211.6 × 103/µL; IQR: 41,750). Median
platelet count was 40.5 × 103/µL (minimum: 11 × 103/µL;
maximum: 455 × 103/µL; IQR 62,750). FLT-3 ligand values
at the time of diagnosis are shown in Figure 1.
The median FLT-3 ligand value during remissioninduction treatment during aplasia was 877 pg/mL
(minimum: 9.18 pg/mL; maximum: 2211 pg/mL). The
median platelet and white cell counts were respectively 14
× 103/µL (minimum: 5 × 103/µL; maximum: 25 × 103/µL)
and 0.7 × 103/µL (minimum: 0.2 × 103/µL; maximum: 1.8
× 103/µL) in the same time period.
After the remission-induction period, median FLT3 ligand value was 61.9 pg/mL (minimum: 35.3 pg/mL;
maximum: 127 pg/mL). Median platelet and white cell
counts were respectively 277 × 103/µL and 7.1 × 103/µL.
Table 1. The demographic specifications of AML patients.
Study group
Age (years)
Mean ± SD

49.92 ± 3.63

Median

50.5

Distribution range

19–90

Sex
Male

12

Female

12

AML type (FAB)
AML-M1

1

AML-M2

14

AML-M4

4

AML-M5

1

CML blastic transformation

3

Biphenotypic

1
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3 ligand value of male subjects was significantly higher
than that of the females (P = 0.009) (median FLT-3 for
males: 16.25 pg/mL; for females: 8.75 pg/mL). During
diagnosis, 12 patients had a coincidental infection while
the others had no sign of infection. There was no statistical
relationship between infection and diagnostic FLT-3 value.
There was also no relation between fever and diagnostic
FLT-3 value (P = 0.788).
There was a reverse relationship between white cell
count and diagnostic FLT-3 ligand value (P = 0.014).
When we analyzed the values of the 9 AML patients who
could be followed during all treatment periods, there was a
negative correlation between white cell and FLT-3 value (P
= 0.024; r = –0.736). There was also a relationship between
diagnostic FLT-3 and platelet count (P = 0.035). When we
compared the diagnostic FLT-3 with the other treatment
periods’ measurements there was a significant increase in
consolidation and remission-induction values (P = 0.008)
(Figure 2).
The analysis of electrolytes such as Na, K, P, and
Ca showed no relation with diagnostic FLT-3 ligand
measurements. On the other hand, there was a negative
relation between FLT-3 ligand and LDH values (P = 0.03).
Figure 1. FLT-3 ligand value at the time of diagnosis.

The median FLT-3 ligand value during consolidation
thrombocytopenia was 1812 pg/mL (minimum: 234.8 pg/
mL; maximum: 2244 pg/mL). The median white cell count
was 1.1 × 103/µL (minimum: 0.3 × 103/µL; maximum: 3
× 103/µL) with 15 × 103/µL median platelet count. The
median FLT-3 value after consolidation was 68.5 pg/mL
(minimum: 43.89; maximum: 231.1 pg/mL). The median
value of white cell count was 4.6 × 103/µL (minimum: 3.1
× 103/µL; maximum: 17.7 × 103/µL). Median platelet value
was 200 × 103/µL during the same treatment period. The
median value trends of white cells, platelet count, and FLT3 ligand during chemotherapy periods of AML patients
are shown in Table 2.
There was no relation between age and diagnostic
value of the FLT-3 ligand (P = 0.862). The diagnostic FLT-

4. Discussion
This study, which measured the level of FLT-3 ligand
during different clinical courses of AML, also analyzed
the relationship of diagnostic ligand grade with age,
sex, electrolytes, and some critical blood parameters.
There was a reverse relationship between diagnostic
and remission-induction white cell count and FLT-3
ligand measurements. The same situation was valid for
diagnostic LDH measurement. There was an elevation
of FLT-3 ligand level in the remission and consolidation
phases according to the diagnostic measurement. Another
statistically significant point was higher diagnostic ligand
levels in male subjects.
Considering the clonal characteristics of AML cells,
the FLT-3 receptor and its ligand activity seem to be
closely associated with prognosis and serial quantities of
leukemic cells. The FLT-3 receptor activating mutations

Table 2. The median value trends of white cells, platelet count, and FLT-3 ligand during chemotherapy periods of AML patients.
FLT-3 ligand (median)

Platelets (median)

White cell count (median)

At diagnosis (n = 24)

139 pg/mL

40.5 × 103/µL

12 × 103/µL

Aplasia (n = 9)

877 pg/mL

14 × 103/µL

0.7 × 103/µL

Before consolidation (n = 9)

61.9 pg/mL

277 × 103/µL

7.1 × 103/µL

Aplasia of consolidation (n = 9)

1812 pg/mL

15 × 103/µL

1.5 × 103/µL

After consolidation (n = 9)

68.5 pg/mL

200,000 × 103/µL

4.6 × 103/µL
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Figure 2. The FLT-3 ligand variation of 9 patients during the treatment period.
con: Consolidation; n: number.

in AML could be related with white cell number in that
disease. The level of the ligand used in this study is in the
opposite direction of the activation of the receptor, which
is associated with low white blood cell count. These results
are statistically significant, especially in the early stages
of treatment. It is possible that after reaching a stable
serum level activity, FLT-3 ligand concentration could be
compensatively elevated to overcome the depressed FLT3 receptor function. FLT-3 ligand elevation could be used
as an opposing factor of white cell proliferative activity in
early-stage AML patients.
An interesting point of our study is the elevated
blood concentration of FLT-3 ligand in the pancytopenic
periods of the treatment phases. This could be the result
of the stem cell activity to increase blood cell amount.
This is in support of the FLT-3 ligand usage in stem cell
transplantation.
The FLT-3 ligand has the potential to stimulate both
the unmutated and the mutated FLT-3 receptor cells. This
stimulation is carried out with a Lyn phosphorylation
mechanism. AML cells are also stimulated by FLT-3
ligand with similar mechanisms. The same proliferative
responses through phosphorylation of Lyn are observed in
wild-type and mutated FLT-3 receptors (10). Our study is
not divided according to the patients’ receptor mutation
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status. In general, the overall FLT-3 ligand levels of AML
patients were analyzed during the course of the study.
Sato et al. (11) examined in vivo FLT-3 ligand inhibition
in AML patients treated with chemotherapy followed by
the FLT-3 inhibitor lestaurtinib. They also tried to explore
the effect of FLT-3 ligand concentration on the response of
therapy. After intensive chemotherapy, FLT-3 ligand levels
increased to a mean of 488 pg/mL on day 15 of induction
cure for newly diagnosed patients, whereas they rose to
a mean of 1148 pg/mL in the relapsed patients. The FLT3 ligand level rose progressively in the followed courses.
They concluded that FLT-3 ligand elevation could be an
obstacle to FLT-3 inhibition. This dramatic increase in the
successive courses supported our FLT-3 ligand rise during
periods of aplasia (11).
Levis et al. (12) performed a randomized trial for
FLT-3 mutant AML in first relapse. Patients received
chemotherapy alone or followed by 80 mg of the FLT-3
inhibitor lestaurtinib twice a day. There was no difference
between control and lestaurtinib treatments according to
overall survival. In the lestaurtinib arm, FLT-3 inhibition
was excessively correlated with remission rate, but target
inhibition on day 15 was achieved in only 58% of patients
receiving lestaurtinib. They also observed a rise of the
FLT-3 ligand throughout the course of therapy. At first
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the measured FLT-3 ligand was less than 20 pg/mL at
baseline. During the aplasia period, there were markedly
elevated FLT-3 ligand levels in all patients. The activity of
lestaurtinib was blunted in this aplasia course. They also
supported, in accordance with our study, the elevation of
FLT-3 ligand in the following treatment periods of AML
(12).
LDH activity in AML is increased as a parameter
correlated with the disease severity and appears to decrease
with AML activity (13). FLT-3 ligand and serum LDH levels
are in an inverse relationship in our study. In contrast to
high FLT-3 ligand levels during aplasia, a decreased LDH
level was observed in the same time period. According to

these results the FLT-3 ligand could be a relevant marker
of AML activity inversely proportional to LDH level.
In conclusion, it may be mentioned that the decrease of
the white cell count during the treatment course of AML
resulted in a reciprocal FLT-3 ligand overexpression. There
was no relation between FLT-3 ligand level and red cell
count together with platelet count. The diagnostic ligand
level was higher in male patients. There was no relationship
between age and diagnostic ligand level. An interesting
point of our study was the inverse relation between LDH
and ligand level. Our study supports the hypothesis that
FLT-3 receptor inhibition during chemotherapy-induced
aplasia causes a compensative ligand overexpression.
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